DNTHDianthus Therapeutics, Inc.
Price
+124%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 17% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for DNTH today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (“C1s”) – enabling less frequent and more convenient self-administered subcutaneous (“S.C.”) injections suitable for a pre-filled pen.
In the company’s own words · 10-K filed Mar 9, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Business segments
Q4 2024 · $1.9MThe company’s own SEC segment disclosure.
- License$1.0M53%
- License$900.0K47%
For the full year FY2025, revenue was $2.0M (−67% year on year) and net income −$162M. Its largest product in Q4 2024 (quarter ended Dec 31, 2024) was License at $1.0M, 53% of the disclosed total, just ahead of License at 47%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H’28.Earnings release · press release
- Mar 26, 2026On March 26, 2026, Dianthus Therapeutics, Inc. (the "Company") posted an updated corporate presentation (the "Presentation") on the investor relations section of its website.Other event · Form 8-K
- Mar 12, 2026On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.